Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5390248 | 0.98 | ADORA2A (0.36) | ADORA2AAHCYADORA2BADORA1MAP2K1 | |
| SCHEMBL3946203 | 0.89 | TSHR (0.33) | TSHR | |
| SCHEMBL5389139 | 0.86 | TSHR (0.30) | TSHR | |
| SCHEMBL5407292 | 0.86 | THRB (0.32) | TSHR | |
| SCHEMBL5392456 | 0.83 | TSHR (0.33) | TSHR | |
| SCHEMBL5393788 | 0.83 | — | — | |
| SCHEMBL5386512 | 0.82 | CSNK2A1 (0.35) | ADORA2ACSNK2A1TSHR | |
| SCHEMBL5383684 | 0.82 | THRB (0.32) | — | |
| SCHEMBL31389306 | 0.81 | TSHR (0.33) | TSHR | |
| SCHEMBL5399382 | 0.81 | ADA (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285136-B2 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL, SA (FR) | 2007-10-23 | — | — | US | disclosed |
| US-20040103487-A1 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040103487-A1 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | KRT18, AOC1, DPYD | ADORA2A 4685/4885AHCY 2625/4885ADORA2B 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.